Related Experiment Video
Updated: May 29, 2026
09:54
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
Metabolic therapy: lessons from liver diseases.
Carmen Garcia-Ruiz1, Montserrat Marí, Anna Colell
1IDIBAPS, Liver Unit-Hospital Clinic, and CIBEREHD, Barcelona, Spain.
Current Pharmaceutical Design
|September 22, 2011
Summary
Fatty liver disease, including alcoholic (ASH) and nonalcoholic steatohepatitis (NASH), may be treated by targeting cholesterol and acidic sphingomyelinase (ASMase). These targets are key in the progression from fat accumulation to liver inflammation and damage.
Area of Science:
- Hepatology
- Metabolic Diseases
- Molecular Biology
Background:
- Fatty liver disease, encompassing ASH and NASH, is a prevalent metabolic disorder.
- The disease progresses from simple steatosis to steatohepatitis, marked by inflammation, cell death, and fibrosis.
- Cholesterol and sphingolipids, like ceramide, are implicated in disease progression and insulin resistance.
Purpose of the Study:
- To investigate the role of cholesterol and ceramide in the transition from steatosis to steatohepatitis.
- To explore the potential of targeting cholesterol and acidic sphingomyelinase (ASMase) for therapeutic intervention in fatty liver disease.
Main Methods:
- Analysis of experimental models and patient data.
- Investigation of cholesterol accumulation and trafficking to mitochondria.
- Examination of ceramide generation pathways involving ASMase.
Main Results:
- Cholesterol accumulation sensitizes the liver to inflammatory cytokines.
- Ceramide generation via ASMase plays a crucial role in disease progression.
- Evidence suggests a pathway involving mitochondrial cholesterol and ceramide in liver damage.
Conclusions:
- Targeting cholesterol and/or ASMase presents a novel therapeutic strategy for ASH and NASH.
- Understanding the molecular mechanisms of lipid metabolism is vital for treating fatty liver disease.
- Interventions aimed at modulating cholesterol and ceramide pathways may halt or reverse disease progression.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:30Liver Physiology
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...